NASDAQ:ADVM - Adverum Biotechnologies News Headlines

$5.99
+0.21 (+3.63 %)
(As of 09/16/2019 12:50 PM ET)
Today's Range
$5.4147
Now: $5.99
$6.09
50-Day Range
$5.36
MA: $11.75
$13.82
52-Week Range
$2.62
Now: $5.99
$16.38
Volume800,834 shs
Average Volume2.39 million shs
Market Capitalization$386.12 million
P/E RatioN/A
Dividend YieldN/A
Beta2.49

Headlines

Adverum Biotechnologies (NASDAQ ADVM) News Headlines

Source:
DateHeadline
28 Healthcare Stocks Moving In Thursdays Pre-Market Session28 Healthcare Stocks Moving In Thursday's Pre-Market Session
www.msn.com - September 13 at 9:47 AM
Adverum Biotechnologies (NASDAQ:ADVM) Given New $8.00 Price Target at SunTrust BanksAdverum Biotechnologies (NASDAQ:ADVM) Given New $8.00 Price Target at SunTrust Banks
www.americanbankingnews.com - September 13 at 9:05 AM
Chardan Capital Cuts Adverum Biotechnologies (NASDAQ:ADVM) Price Target to $6.00Chardan Capital Cuts Adverum Biotechnologies (NASDAQ:ADVM) Price Target to $6.00
www.americanbankingnews.com - September 13 at 8:19 AM
Does This Macular Degeneration Study Deserve More Credit?Does This Macular Degeneration Study Deserve More Credit?
247wallst.com - September 12 at 4:43 PM
Adverum Bio down 3% premarket on data from early-stage ADVM-022 IVT gene therapy trialAdverum Bio down 3% premarket on data from early-stage ADVM-022 IVT gene therapy trial
seekingalpha.com - September 12 at 4:43 PM
Heres Why Adverums Shares Saw a Lower Price TodayHere's Why Adverum's Shares Saw a Lower Price Today
www.fool.com - September 12 at 4:43 PM
Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMDAdverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD
finance.yahoo.com - September 12 at 4:43 PM
Adverum Shares Sink After Phase 1 Readout From Wet AMD Gene Therapy TrialAdverum Shares Sink After Phase 1 Readout From Wet AMD Gene Therapy Trial
finance.yahoo.com - September 12 at 4:43 PM
Adverum Biotechnologies Inc (NASDAQ:ADVM) Receives Consensus Recommendation of "Hold" from BrokeragesAdverum Biotechnologies Inc (NASDAQ:ADVM) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 11 at 2:12 AM
Adverum Biotechnologies Inc (NASDAQ:ADVM) Expected to Post Quarterly Sales of $480,000.00Adverum Biotechnologies Inc (NASDAQ:ADVM) Expected to Post Quarterly Sales of $480,000.00
www.americanbankingnews.com - September 11 at 1:50 AM
Zacks: Brokerages Anticipate Adverum Biotechnologies Inc (NASDAQ:ADVM) Will Post Earnings of -$0.27 Per ShareZacks: Brokerages Anticipate Adverum Biotechnologies Inc (NASDAQ:ADVM) Will Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - September 9 at 7:15 PM
Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual MeetingAdverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual Meeting
finance.yahoo.com - September 5 at 11:18 AM
Stock Traders Purchase High Volume of Adverum Biotechnologies Call Options (NASDAQ:ADVM)Stock Traders Purchase High Volume of Adverum Biotechnologies Call Options (NASDAQ:ADVM)
www.americanbankingnews.com - September 5 at 7:45 AM
The Keys to Successfully Timing the Markets - September 04, 2019The Keys to Successfully Timing the Markets - September 04, 2019
finance.yahoo.com - September 4 at 9:45 AM
Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in OctoberAdverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October
finance.yahoo.com - August 29 at 7:43 AM
Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?
finance.yahoo.com - August 27 at 8:16 PM
The Keys to Successful Timing the Markets - August 15, 2019The Keys to Successful Timing the Markets - August 15, 2019
finance.yahoo.com - August 15 at 11:09 AM
Edited Transcript of ADVM earnings conference call or presentation 8-Aug-19 8:30pm GMTEdited Transcript of ADVM earnings conference call or presentation 8-Aug-19 8:30pm GMT
finance.yahoo.com - August 12 at 11:46 AM
Adverum Biotechnologies EPS beats by $0.04Adverum Biotechnologies EPS beats by $0.04
seekingalpha.com - August 9 at 8:27 AM
Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue EstimatesAdverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 9 at 8:27 AM
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Should You Buy?Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Should You Buy?
www.nasdaq.com - August 2 at 12:58 AM
Is the Options Market Predicting a Spike in Adverum (ADVM) Stock?Is the Options Market Predicting a Spike in Adverum (ADVM) Stock?
finance.yahoo.com - July 27 at 8:44 AM
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2019 Financial Results and Provide Corporate UpdatesAdverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2019 Financial Results and Provide Corporate Updates
finance.yahoo.com - July 26 at 7:26 AM
What Makes Adverum Biotechnologies (ADVM) a New Strong Buy StockWhat Makes Adverum Biotechnologies (ADVM) a New Strong Buy Stock
finance.yahoo.com - July 16 at 7:23 PM
5 Best Biotech Stocks of 2019 So Far5 Best Biotech Stocks of 2019 So Far
finance.yahoo.com - July 12 at 8:19 AM
Adverum (ADVM) Jumps: Stock Rises 5.1%Adverum (ADVM) Jumps: Stock Rises 5.1%
finance.yahoo.com - July 11 at 6:30 PM
ADVMs Rise From $4 To $14; Did You Ride The Rally? ADVM's Rise From $4 To $14; Did You Ride The Rally?
www.rttnews.com - July 9 at 6:35 AM
Adverum up 10% ahead of ADVM-022 data readoutAdverum up 10% ahead of ADVM-022 data readout
seekingalpha.com - July 8 at 6:54 PM
Adverum Biotechnologies to Present Data at Upcoming ConferencesAdverum Biotechnologies to Present Data at Upcoming Conferences
finance.yahoo.com - July 8 at 8:13 AM
3 Biotechs That Have Doubled This Year (Acquisition Next?)3 Biotechs That Have Doubled This Year (Acquisition Next?)
finance.yahoo.com - July 2 at 6:44 PM
The Adverum Biotechnologies (NASDAQ:ADVM) Share Price Has Gained 252%, So Why Not Pay It Some Attention?The Adverum Biotechnologies (NASDAQ:ADVM) Share Price Has Gained 252%, So Why Not Pay It Some Attention?
finance.yahoo.com - June 23 at 6:37 PM
Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMDAdverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMD
finance.yahoo.com - June 10 at 6:56 PM
Adverum Biotechnologies: A High Risk/High Reward Biotech Play In 2019Adverum Biotechnologies: A High Risk/High Reward Biotech Play In 2019
seekingalpha.com - May 25 at 8:13 AM
Adverum Biotechnologies, Inc. (ADVM) Shares March Higher, Can It Continue?Adverum Biotechnologies, Inc. (ADVM) Shares March Higher, Can It Continue?
finance.yahoo.com - May 24 at 7:00 PM
Updated Investment Thesis On Adverum BiotechnologiesUpdated Investment Thesis On Adverum Biotechnologies
seekingalpha.com - May 21 at 6:15 AM
All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to BuyAll You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy
www.nasdaq.com - May 18 at 6:48 AM
Adverum Biotechnologies Inc.Adverum Biotechnologies Inc.
www.barrons.com - May 16 at 7:49 PM
Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMDAdverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD
finance.yahoo.com - May 16 at 7:49 PM
Adverum Biotechnologies Reports First Quarter 2019 Financial Results and Provides Corporate UpdateAdverum Biotechnologies Reports First Quarter 2019 Financial Results and Provides Corporate Update
www.globenewswire.com - May 8 at 7:41 PM
Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue EstimatesAdverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 8 at 7:41 PM
Adverum Biotechnologies Announces Board ChangesAdverum Biotechnologies Announces Board Changes
finance.yahoo.com - May 2 at 8:04 PM
Adverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 Gene Therapy in Wet AMD at the ASGCT 22nd Annual MeetingAdverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 Gene Therapy in Wet AMD at the ASGCT 22nd Annual Meeting
finance.yahoo.com - May 2 at 8:19 AM
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
finance.yahoo.com - May 1 at 7:32 PM
Adverum Biotechnologies Presents First Preclinical Data on Dosing Contralateral Eye with ADVM-022 Gene Therapy for Wet AMD at the ARVO 2019 Annual MeetingAdverum Biotechnologies Presents First Preclinical Data on Dosing Contralateral Eye with ADVM-022 Gene Therapy for Wet AMD at the ARVO 2019 Annual Meeting
finance.yahoo.com - April 30 at 6:57 PM
Adverum Biotechnologies Appoints Thomas Leung as Chief Financial OfficerAdverum Biotechnologies Appoints Thomas Leung as Chief Financial Officer
finance.yahoo.com - April 24 at 6:41 PM
Adverum Announces Clinical Hold, But It Should Not Hinder Its Gene Therapy PathAdverum Announces Clinical Hold, But It Should Not Hinder Its Gene Therapy Path
seekingalpha.com - April 17 at 7:32 PM
Adverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVOAdverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVO
finance.yahoo.com - April 16 at 7:50 PM
Adverum down 7% on FDA suspension of gene therapy trialAdverum down 7% on FDA suspension of gene therapy trial
seekingalpha.com - April 15 at 7:30 PM
Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMDAdverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD
www.marketwatch.com - April 15 at 7:30 PM
Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMDAdverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD
finance.yahoo.com - April 15 at 7:30 PM
This page was last updated on 9/16/2019 by MarketBeat.com Staff

Featured Article: What is Liquidity?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel